We are pleased to announce the new dates and location for the Trans-Pacific Health Sciences Dialogue: October 14-15, 2015
The Joseph B. Martin Conference Center at Harvard Medical School, Boston, MA
More information coming soon.
Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an event for Asian and North American senior biopharmaceutical executives, KOLs, select professional services industry advisors and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment.
Industry News from BioCentury
- Genfit reports Phase II NASH dataGenfit S.A. (Euronext:GNFT) said GFT505 missed the primary endpoint of the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH) according to the study's initial design. GFT505 met the endpoint after the company reanalyzed its data to account for baseline disease severity and trial site heterogeneity.
Genfit expects to start a Phase III trial of the dual peroxisome proliferation activated receptor (PPAR) alpha and delta agonist by YE15. Genfit lost EUR 2.25 to EUR 50.85 in Paris on Thursday; it reported the data after market close. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), which plans to begin a Phase III study this half of OCA obeticholic acid to treat NASH, gained $22.05 to $282.69 on Thursday.
The primary endpoint of GOLDEN-505 was disease resolution, defined as reaching a NAFLD Activity Score (NAS) of zero on any one of three histological components, without worsening fibrosis. Genfit said there was an unexpectedly high incidence of disease resolution in the trial's placebo arm among patients with mild disease (NAS=3). The study enrolled 274 patients with NASs ranging from 3 to 8.
Genfit said the treatment met the endpoint in the total (p=0.016) and intent-to-treat (p=0.027) populations after the company applied a statistical analysis that controlled for baseline disease severity, as well as for the high number of trial sites with a small sample size. It did not release uncorrected results.
Genfit management said on a conference call that the upcoming Phase III trial will exclude patients with a baseline NAS of 3 and will measure fibrosis. The company said the 52-week Phase II trial was too short to assess improvement in fibrosis.
The company said GFT505 led to improvements in liver, cardio-metabolic and inflammatory biomarkers, and resulted in no adverse cardiac events, cancer signals or deaths.
Industry News from PharmAsia
- Indonesia Penalizes Kalbe Over Suspected Drug Mix-Up DeathsIndonesia’s food and drug agency has ordered the country’s largest pharmaceutical company, Kalbe Farma, to suspend production of some of its drugs over a suspected label mix-up that led to the death of two patients.<img src="//feeds.feedburner.com/~r/_PharmAsiaNews/~4/KMbkFAQLnaY" height="1" width="1" alt="" />